NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.
Total second-quarter revenue rose 11% ye
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know. NeoG...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the ...
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) a...
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi...
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Over the past six months, NeoGenomics’s shares (currently trading at $9.01) have posted a disappointing 13.4% loss, well below the S&P 500’s 7.1% gain. This ...
NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results this Tuesday after market close. Here’s what investors should know. ...
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 4.1% in the afternoon session after the company announced that...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl...
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...
